← Oncology Approval Tracker

FDA DECISION ·

Brukinsa

zanubrutinib · BeiGene USA

FDA approvalNew or expanded indicationCLL / SLL
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.

LAMPGEN ANALYSIS

Why it matters

The action added a BTK inhibitor option for CLL and SLL across treatment settings.

What research teams should watch

Document treatment history and assess comorbidities and concomitant medications when evaluating fit.

PRIMARY RECORDS

Sources